500 mcg each: Draw 10 units (0.1 mL) standard BPC-157 dose
Reported complications in GLP-1 lawsuits include gastroparesis, bowel obstruction, ileus, cyclic vomiting syndrome, gallbladder disease, pulmonary aspiration during surgery, and non-arteritic anterior ischemic optic neuropathy (NAION), a rare optic nerve injury associated with sudden and potentially permanent vision loss
Rusfertide Hepcidin Mimetic: Phase 3 VERIFY Trial Data and FDA Priority Review Status Rusfertide hit a 77% clinical response rate in the Phase 3 VERIFY trial for polycythemia vera, and FDA Priority Review now targets a Q3 2026 decision
Looking at before and after results on semaglutide or tirzepatide before and after transformations makes the clinical percentages feel concrete and real
Compounding pharmacies are pharmacies
These results are not being positioned as guarantees, but they are enough to generate serious interest